Carol Lattouf, MD
Dermatology · Miami, FLNPI 1043519564
Payments from drug & device makers
Across 226 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$688
- Galderma Laboratories, L.p.$652
- Sanofi$436
- Novartis$402
- Regeneron Healthcare Solutions, Inc.$269
- plus $1K from 14 others
What the payments were for
- Food & beverage$5,15898%
- Education$1142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $1,365 |
| Johnson & Johnson | 31 | $688 |
| Galderma Laboratories, L.p. | 19 | $652 |
| Sanofi | 15 | $436 |
| Novartis | 18 | $402 |
| Regeneron Healthcare Solutions, Inc. | 10 | $269 |
| Amgen | 11 | $268 |
| Lilly USA, LLC | 10 | $220 |
| LEO Pharma Inc. | 11 | $202 |
| Pfizer | 12 | $195 |
| Sun Pharmaceutical Industries Inc. | 6 | $126 |
| Biofrontera Inc. | 6 | $122 |
| Bristol Myers Squibb | 3 | $63 |
| Helsinn Therapeutics (U.S.), Inc. | 4 | $63 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $48 |
| Incyte Corporation | 2 | $38 |
| Pierre Fabre Pharmaceuticals, Inc. | 3 | $37 |
| Verrica Pharmaceuticals Inc. | 1 | $34 |
| Boehringer Ingelheim | 1 | $29 |
| UCB, Inc. | 1 | $18 |
How this compares
$5,272 in reported general payments places this provider in the 60th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 49 | $3,193 |
| Tacrolimus | 13 | $1,919 |
| Doxycycline Hyclate | 61 | $1,675 |
| ValacyclovirValacyclovir Hcl | 60 | $1,564 |
| Fluocinonide | 40 | $1,385 |
| Clobetasol Propionate | 35 | $1,324 |
| Ketoconazole | 56 | $1,111 |
| Triamcinolone Acetonide | 111 | $752 |
| Metronidazole | 17 | $679 |
| Hydrocortisone | 86 | $593 |
| Mupirocin | 45 | $356 |
| Hydroxychloroquine Sulfate | 15 | $332 |
| Clindamycin Phosphate | 15 | $281 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 18 | $194 |
| Minoxidil | 14 | $122 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Miami
- Hector Wiltz JrMiami$6.4M
- Francisco KerdelMiami$5.1M
- Jill WaibelMiami$4.3M
- Gil YosipovitchMiami$3.7M
- Mercedes GonzalezMiami$3.6M
- Giovanna CioccaMiami$3.2M
- David RodriguezMiami$3M
- Hadar Lev-TovMiami$2.5M
- Leslie BaumannMiami$2.3M
- Mojgan HosseinipourMiami$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.